Caricamento...
Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma
Third-line sunitinib is occasionally used for selected patients with metastatic renal cell carcinoma (mRCC). The aim of the present study was to evaluate the clinical significance of third-line sunitinib after failure of first-line cytokine therapy and second-line sorafenib in patients with clear-ce...
Salvato in:
| Pubblicato in: | Mol Clin Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
D.A. Spandidos
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6781811/ https://ncbi.nlm.nih.gov/pubmed/31616562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1924 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|